Last reviewed · How we verify
Placebo for Elagolix
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trials for Elagolix.
At a glance
| Generic name | Placebo for Elagolix |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In Phase 3 trials for Elagolix, placebo serves as the comparator arm to demonstrate that observed clinical benefits are attributable to the active drug rather than natural disease progression or psychological factors.
Approved indications
- Control arm in Phase 3 clinical trials for Elagolix
Common side effects
Key clinical trials
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain (PHASE3)
- Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (PHASE3)
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (PHASE3)
- Brain Blood Flow Responses to Stress: Sex Differences (PHASE4)
- Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PHASE3)
- Role of Menopause in Thermoregulation (PHASE4)
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain (PHASE3)
- Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Elagolix CI brief — competitive landscape report
- Placebo for Elagolix updates RSS · CI watch RSS
- AbbVie portfolio CI